Evidence map›Paper›PMID 34304088›Full record

ArticleJournal of clinical virology : the official publication of the Pan American Society for Clinical Virology2021

SARS-CoV-2 serology: Validation of high-throughput chemiluminescent immunoassay (CLIA) platforms and a field study in British Columbia.

Inna Sekirov, Vilte E Barakauskas, Janet Simons, Darrel Cook, Brandon Bates, Laura Burns, Shazia Masud, Marthe Charles, Meghan McLennan, Annie Mak and 7 more

Abstract read
In one paragraph

Article in Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Observational
  5. Review
  6. Article
  7. Review
  8. Review
  9. Serial cross-sectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2022
    Article
  10. Article
  11. Paediatrics & child health · 2022
    Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Inna SekirovBCCDC Public Health Laboratory, BC Centre for Disease Control, Vancouver BC, Canada; Pathology and Laboratory Medicine, University of British Columbia, Vancouver BC, Canada.
Vilte E BarakauskasPathology and Laboratory Medicine, University of British Columbia, Vancouver BC, Canada; BC Children's and Women's Hospital, Vancouver BC, Canada.
Janet SimonsBC Children's and Women's Hospital, Vancouver BC, Canada; Department of Laboratory Medicine, Providence Health Care, Vancouver BC, Canada.
Darrel CookBCCDC Public Health Laboratory, BC Centre for Disease Control, Vancouver BC, Canada.
Brandon BatesPathology and Laboratory Medicine, University of British Columbia, Vancouver BC, Canada; BC Children's and Women's Hospital, Vancouver BC, Canada.
Laura BurnsPathology and Laboratory Medicine, University of British Columbia, Vancouver BC, Canada; BC Children's and Women's Hospital, Vancouver BC, Canada.
Shazia MasudPathology and Laboratory Medicine, University of British Columbia, Vancouver BC, Canada; Surrey Memorial Hospital, Surrey BC, Canada.
Marthe CharlesPathology and Laboratory Medicine, University of British Columbia, Vancouver BC, Canada; Vancouver General Hospital, Vancouver BC, Canada.
Meghan McLennanProvincial Health Services Authority, Vancouver BC, Canada.
Annie MakBCCDC Public Health Laboratory, BC Centre for Disease Control, Vancouver BC, Canada.
Navdeep ChahilBCCDC Public Health Laboratory, BC Centre for Disease Control, Vancouver BC, Canada.
Rohit VijhVancouver Coastal Health, Vancouver BC, Canada.
Althea HaydenVancouver Coastal Health, Vancouver BC, Canada.
David GoldfarbPathology and Laboratory Medicine, University of British Columbia, Vancouver BC, Canada; BC Children's and Women's Hospital, Vancouver BC, Canada.
Paul N LevettBCCDC Public Health Laboratory, BC Centre for Disease Control, Vancouver BC, Canada; Pathology and Laboratory Medicine, University of British Columbia, Vancouver BC, Canada.
Mel KrajdenBCCDC Public Health Laboratory, BC Centre for Disease Control, Vancouver BC, Canada; Pathology and Laboratory Medicine, University of British Columbia, Vancouver BC, Canada.
Muhammad MorshedBCCDC Public Health Laboratory, BC Centre for Disease Control, Vancouver BC, Canada; Pathology and Laboratory Medicine, University of British Columbia, Vancouver BC, Canada. Electronic address: Muhammad.Morshed@bccdc.ca.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSARS-CoV-2 antibody testing is required for estimating population seroprevalence and vaccine response studies. It may also increase case identification when used as an adjunct to routine molecular testing. We performed a validation study and evaluated the use of automated high-throughput assays in a field study of COVID-19-affected care facilities.

methodsSix automated assays were assessed: 1) DiaSorin LIAISON

resultsAll assays had sensitivities >90% in the field study, while in the validation study, 5/6 assays were >90% sensitive and DiaSorin was 79% sensitive. Specificities and negative predictive values were >95% for all assays. Field study estimated positive predictive values at 1-10% disease prevalence were 100% for Siemens, Abbott and Roche, while DiaSorin and Ortho assays had lower PPVs at 1% prevalence, but PPVs increased at 5-10% prevalence. In the field study, addition of serology increased diagnoses by 16% compared to PCR testing alone.

conclusionsAll assays evaluated in this study demonstrated high sensitivity and specificity for samples collected at least 14 days post-symptom onset, while sensitivity was variable 0-14 days after infection. The addition of serology to the outbreak investigations increased case detection by 16%.

Indexed as

COVID-19SARS-CoV-2Antibodies, ViralBritish ColumbiaHumansImmunoassaySensitivity and SpecificitySeroepidemiologic StudiesAntibodies, ViralCOVID-19Outbreak investigationSARS-CoV-2Serologic testing

Identifiers

PMID34304088
PMCPMC8282439

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.